MedTrace Logo

A Prospective, Multicenter, Diagnostic Study Evaluating 68Ga-BCMA PET/CT for Targeting BCMA Expression in Multiple Myeloma.

NCT07319897 · Status: NOT_YET_RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2026-01-06

No results posted yet for this study

Summary

This is a prospective, multicenter, diagnostic imaging study designed to evaluate the diagnostic performance and clinical utility of BCMA-targeted Positron Emission Tomography/Computed Tomography (PET/CT) in patients with multiple myeloma and other palsma cell disorders. The study aims to non-invasively visualize and quantify the whole-body biodistribution of BCMA expression.

Conditions

  • Multiple Myeloma
  • Multiple Myeloma and Malignant Plasma Cell Neoplasms
  • Multiple Myeloma and Plasma Cell Neoplasm

Interventions

DIAGNOSTIC_TEST

68Ga-BCMA PET/CT

Intravenous administration of the investigational BCMA-targeted radiopharmaceutical, followed by a whole-body PET/CT scan performed per a standardized protocol.

Sponsors & Collaborators

  • The First Hospital of Jilin University

    collaborator OTHER

  • The Second Hospital of Hebei Medical University

    collaborator OTHER

  • Beijing Anzhen Hospital

    collaborator OTHER

  • Beijing Tsinghua Changgeng Hospital

    collaborator OTHER

  • Peking University First Hospital

    lead OTHER

Principal Investigators

  • Lei Kang, M.D, Ph.D · Peking University First Hospital

  • Yujun Dong, M.D, Ph.D · Peking University First Hospital

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-12-25
Primary Completion
2027-12-30
Completion
2027-12-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07319897 on ClinicalTrials.gov